Journal of the National Cancer Institute Advance Access originally published online on December 9, 2008
JNCI Journal of the National Cancer Institute 2008 100(24):1748-1750; doi:10.1093/jnci/djn458
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2008.
NEWS |
Helicobacter pylori: Good Side Complicates Efforts To Combat Bad Side
| The first 150 words of the full text of this article appear below. |
It sounds all too obvious: Screen people for Helicobacter pylori, a known cause of gastric cancer; then treat the infection with antibiotics and save hundreds of thousands of lives each year.
But it's not that simple, and a debate about the pros and cons of population screening and treatment for H. pylori continues to simmer. In July, a new study in The Lancet added fresh fuel to the discussion. Masahiro Asaka, M.D., of Hokkaido University Graduate School of Medicine in Japan and colleagues in the Japan GAST Study Group studied 544 patients with early gastric cancer and H. pylori infection. The patients were randomized to receive either standard care for gastric cancer or standard care plus antibiotics to eradicate the infection. Among those who took the antibiotics, nine developed new cancers compared with 14 among those receiving standard care. The difference was statistically significant.
In an accompanying editorial, Nicholas
Pros
Cons
Different Risks
Doing Something Now